Antibacterial Agents TRIZ Cases

A citrate coordination complex stabilizes an oral boronic acid beta-lactamase inhibitor with ceftibuten, enabling immediate-release tablets for resistant infections.

Carrier-bound water-soluble chelators sequester iron outside target cells, limiting metal uptake and suppressing cell growth.

C-terminal kinocidin peptides use cationic amphipathic helices to disrupt microbial membranes and inhibit resistant bacteria and fungi.

Distinct eravacycline bis-HCl crystal forms improve stability, solubility, and flow while supporting high-purity pharmaceutical production.

Stable tosylate, HCl, and mesylate polymorphs improve tetracycline stability and bioavailability while enabling safer, more consistent dosing.

Structural tuning of tolfenpyrad derivatives improves Francisella inhibition while limiting macrophage toxicity and resistance risk.

Two probiotic strains are combined at defined ratios to improve colitis relief, gut microecology, inflammatory balance, and short-chain fatty acids.

Click-chemistry naphthoquinone oxazole derivatives suppress inflammatory cytokines and improve activity against drug-resistant Candida and MRSA.

Specific microbial consortia reshape the rumen microbiome to raise milk yield, improve feed use, and cut methane emissions.

Controlled subcutaneous or intravenous phenol dosing reduces viral dyspnoea and ARDS-linked oxidative stress while limiting toxicity.

Fluorophore-quencher DNA assays detect supercoiling changes to rapidly find DNA gyrase inhibitors for resistant bacterial infections.

Targeted CRISPR nuclease cutting kills microbes within minutes and sustains infection or biofouling control with less frequent dosing.

A low-PZC AlPO4 adjuvant helps stabilize MenB fHBP antigens while boosting homologous and heterologous immune response.

A simplified solvent extraction and crystallization route improves curcumin purification while reusing turmeric residue to cut waste and cost.

Small-molecule agonists raise cAMP in Mtb via Rv1625c, blocking cholesterol metabolism and boosting current TB therapies.

Cyclophane-forming polypeptides use RiPP biosynthesis to inhibit CRE and ESBL-E Gram-negative bacteria at low MIC levels.

Targeting the conserved Salmonella LPS inner core, the J5 dLOS/OMP vaccine broadens protection and supports coverage of resistant strains.

Direct antibacterial and urease inhibition from zastaprazan boosts antibiotic synergy against resistant H. pylori and improves eradication.

A modified oxazolidinone maintains M. tuberculosis activity while reducing mitochondrial inhibition, lowering myelosuppression risk.

Combining urolithin with PD-1 blockade boosts T-cell activation and helps overcome immune evasion in solid tumor treatment.

Targeting PcrV with antibodies blocks Pseudomonas T3SS toxin delivery and membrane pore damage, helping prevent drug-resistant infection.

Crystalline boronic acid derivatives inhibit β-lactamase to restore antibiotic activity against resistant bacteria through controlled synthesis and crystallization.

Thermally responsive gold nanoparticles use R2ab-mediated biofilm binding to improve implant-site photothermal killing and limit nonspecific binding.

Targeting LptA with 16-residue peptidomimetics helps kill Gram-negative bacteria while limiting cytotoxicity and resistance.

Targeted bacteriophage mixtures kill Staphylococcus aureus and biofilms while limiting resistance, toxicity, and gut flora disruption.

Novel compounds such as NPIMA and BPOET kill persister and VBNC bacteria in biofilms and on surfaces where antibiotics fail.

By inserting a donor scaffold domain into an antibody scaffold, this case boosts binding diversity and stability while preserving half-life.

Monohydrazide compounds suppress drug-resistant A. baumannii and biofilms while avoiding resistance induction and limiting mammalian cytotoxicity.

Direct vaginal delivery of Lactobacillus probiotics avoids gastric loss, shortens treatment, and reduces irritation from applicators.

Crystallized phthalocyanine with controlled X-ray diffraction enables higher singlet oxygen generation where visible light cannot reach.

A mucoadhesive polymer and surfactant coating helps nasal formulations block virus transport, capture droplets, and stay longer on mucosal tissue.

Beta-cyclodextrin and D-mannitol improve solubility and storage stability of this injectable composition while avoiding excess solvents.

A saponin-sterol-CpG composition activates innate immunity without antigen, enabling rapid protective response in bovines.

A bentonite-vancomycin complex treats CDI at lower antibiotic doses by adsorbing toxins and reducing side effects and resistance.

Reverse emulsion polymerization creates a stable, injectable vaccine adjuvant with higher aqueous phase content and improved antigen loading.

A two-strain probiotic composition improves infectious pneumonia control by reducing lung inflammation and avoiding antibiotic side effects.

A probiotic wound composition boosts nitric oxide, fights biofilm-linked bacteria, and promotes re-epithelialization without antibiotic side effects.

Specific feedstocks boost cell metabolism and nitroimidazole activation, increasing microbial susceptibility at lower antibiotic doses.

Low-dose propane-1,2-diol with a bioadhesive polymer reduces TNF-α and IL-2 in mucous membranes and skin while limiting dehydration and toxicity.

Boron-based beta-lactamase inhibitors paired with oral beta-lactam antibiotics help restore activity against resistant gram-negative infections.

A bilayer tablet separates probenecid and a beta-lactam to sustain antibiotic exposure, improve bioavailability, and lower resistance risk.

Targeted NspA amino acid substitutions reduce factor H binding while preserving bactericidal antibody responses against N. meningitidis.

Selective anti-PACAP antibodies block vasodilation, photophobia, and neuronal activation to treat migraine-related pain with fewer side effects.

Targets Wolbachia in filarial worms with pyridopyrimidine compounds to shorten therapy and broaden safe use across patient groups.

Uses siderophore uptake and β-lactamase cleavage to carry antibiotics into Gram-negative bacteria and release them inside the cell.

A tetracycline-divalent metal carboxylate complex extends periodontal antibiotic retention, improves aqueous stability, and supports uniform release.

Pulmonary pβCD nanoparticles act as both TB drug carriers and intrinsic antibacterials by disrupting macrophage lipid rafts and colonization.

Neisseria-specific nucleic acids use DNA uptake sequences and methylation mismatch to kill resistant pathogens while sparing commensal strains.

Encochleated and lipid-based Amphotericin B with antibiotics improves respiratory absorption while reducing toxicity and treating infection-driven inflammation.

Oral β-glucan-rich yeast cell wall extract helps prevent Lawsonia ileitis in pigs while avoiding cumbersome injection-based vaccination.

Bulk-integrated antimicrobial polymers prevent infection without relying on surface coatings that erode over time.

Klebicins overcome antibiotic resistance by cleaving lipid II or forming pores in Klebsiella membranes.

Pithecellobium clypearia Benth extract acts as a natural sensitizer for antibiotics, reducing minimum inhibitory concentrations by up to 99.2%.

Activated protein C degrades extracellular histones, resolving endothelial damage and improving sepsis survival rates.

Macrocyclic peptides inhibit PD-1/PD-L1 and CD80/PD-L1 interactions, preventing immune evasion and suppressing tumor growth.

Chemical synthesis of cajanine analogues overcomes limited natural sources to provide diverse structures with enhanced pharmacological activities.

Plant-produced Yersinia pestis antigens induce protective immune responses while resolving vaccine safety and manufacturing accessibility trade-offs.

A hard tissue repair composition uses an organoboron initiator to control viscosity and exothermic properties during polymerization.

Reacting 5-fluoro-1,3-dimethyl-1H-pyrazole-4-carbonyl fluoride with aniline derivatives to produce carboxamides without acid acceptors.

Linear and cyclic peptoid oligomers exhibit potent antimicrobial activity against gram-positive and gram-negative bacterial strains.

Fused-bicyclic moieties attached to carbonyl groups enhance FabI inhibition potency, resolving inadequate treatment of bacterial infections.

A core-and-shell dosage form uses three-dimensional printing to create a continuous release barrier.

Structural optimization of heterocyclic compounds improves bioavailability and half-life while reducing first-pass metabolism.

Carbon fiber and titanium electrodes eliminate removal delays by maintaining MR conditional status for safe in-scan electrophysiological recording.

Combustion synthesized porous ceramic eliminates drug resistance and side effects by replacing chemical mechanisms with physical ROS generation.

Genomic informatics identifies novel surface-exposed Staphylococcus aureus proteins as vaccine antigens.

Combining pyrroloquinoline with aminoglycosides kills multiplying and stationary phase bacteria through synergistic antimicrobial activity.

Heavy chain antigen combined with adjuvants overcomes limited serotype coverage to deliver broad immunity against lethal Clostridium botulinum challenges.

Specialized immunonutrition supplement stabilizes arginine levels to regulate immune response.

Pyrazolopyrimidine derivatives target CK2 and PIM kinases with high specificity, reducing off-target effects common in non-selective treatments.

Microwave heating induces vitreous transition in gluten proteins, reducing antigenicity to 0-20 ppm and eliminating immunogenicity for celiac patients.

Branched polyethyleneimine particles maintain structural integrity during balloon catheter procedures while maximizing local uptake into vessel walls.

Tylosin A derivatives with esterase-resistant substituents overcome short half-life and poor oral bioavailability.

Segmented 2-Aza-bicyclo[2.2.2]octane amides resolve the contradiction between inhibition activity and selectivity against other cysteine proteases.

Hypohalite and lactoferrin compositions penetrate protective biofilm matrices, enabling antimicrobial agents to reach shielded bacteria.

S-triazine derivatives bind vimentin to alter its spatial distribution and mobility, inhibiting cell endocytosis and exosomal release.

TC-PTP inhibitors block immunosuppressive signaling to activate dendritic cells, restoring JAK-STAT pathway function against tumors.

Small molecule 2-oxo-imidazopyridines replace complex protein therapies to selectively inhibit BTK and treat autoimmune disorders.

Furo[3,4-b]quinolone compounds target DNA gyrase to combat drug-resistant bacteria and tuberculosis.

Substituted quinoline derivatives inhibit the F1F0 ATP synthase enzyme, overcoming antibiotic resistance in gram-positive and gram-negative bacteria.

Extracellular targeted drug conjugates use non-cleavable linkers to attach antibodies to therapeutic agents for direct extracellular action.

Arabinogalactanase enzymes replace mechanical lysis to extract mycobacterial DNA from complex sputum samples.

Acid formulation at pH 1.5 to 2.5 reduces respiratory pathogen loads through cell lysis, countering antimicrobial resistance.

Bicycloheteroaryl substituted fused diazabicycloalkane derivatives selectively target alpha7 and alpha4beta2 nicotinic acetylcholine receptors.

Recombinant lysin enzymes degrade peptidoglycan structures in bacterial cell walls to cause lysis, addressing antibiotic resistance and allergic reactions.

A herbal composition protects freshwater fish liver and intestines while boosting immunity through synergistic plant extracts.

Biodegradable polymer bioactive conjugates resolve uncontrolled dosing by segmenting drug release from backbone degradation using cleavable linkers.

Eliminating intermediate isolation steps during nitration and thermal rearrangement reduces explosion risks while maintaining high yield.

Encapsulating CpG oligodeoxynucleotides in sterically stabilized cationic liposomes protects them from serum degradation, extending therapeutic efficacy.

Biomarker analysis of gut microbiota dysbiosis enables non-invasive prediction of Clostridium difficile infection susceptibility.

Balanced C6-C12 fatty acid ratios eliminate pathogens while maintaining gastrointestinal pH stability.

Oral probiotic strains restore commensal flora balance while reducing Staphylococcus aureus adhesion and survival in mastitis treatment.

Hydantoin-modified cyclic peptides resolve selectivity and stability trade-offs by achieving low nanomolar MC-4 affinity.

Antibodies bind alpha toxin monomers to block pore formation, treating antibiotic-resistant infections.

Single AAV vectors express monospecific and bispecific antibodies, reducing production costs while overcoming limited transgene packaging capacity.

Optimized 0.2% formaldehyde inactivates Bordetella parapertussis virulence while preserving antigenicity for effective protection at reduced doses.

Coupling cryptate compounds to carbonyl molecules through primary amine condensation at controlled pH levels.

Phenylcapsaicin additives reduce Salmonella colonization without antibiotic resistance or corrosion issues.